FDA approves Aurobindo’s generic Actonel

DAYTON, N.J. — Aurbindo Pharma on Thursday announced that the Food and Drug Administration had approved its generic of Actonel (risedronate sodium) tablets. The drug, which is indicated to treat osteoporosis, will be available in 5-, 30- and 35-mg dosage strengths. 

 

The drug had about $185.4 million in U.S. sales for the 12 months ended September 2015, according to IMS Health data.